Gilead Sciences, Inc.

More coverage

STAT+: Why Gilead can’t stop talking about its ambitions in immunology

Markets 12 h ago

Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?

Markets 19 d ago

Is Gilead Sciences Stock Outperforming the S&P 500?

Markets 21 d ago

Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited.

Markets 37 d ago

Gilead yanks out a thorn in its side in major court ruling

Markets 38 d ago

Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?

Markets 40 d ago also on MGNX

Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)’s Partnership Create the Next Big Pharma Growth Engine

Markets 42 d ago also on MRK

Gilead Sciences options activity points to institutional conviction on 2026 upside

Markets 44 d ago

Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade)

Markets 45 d ago

Key HIV stat over 70% leaves BofA siding with Gilead

Markets 47 d ago 2 sources

Congo Ebola Outbreak: Merck Ervebo Vaccine, Gilead Remdesivir Eyed for Wider Use

Markets 48 d ago

Gilead Sciences: A Strong Quarter Hidden Behind Ugly Earnings

Earnings 49 d ago